- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01294007
Radiographic Analysis Using PureGen Versus Autologous Bone in Posterolateral Fusion (PLF)
A Radiographic Analysis Using PureGen Osteoprogenitor Cell Allograft Versus Autologous Bone in Posterolateral Fusion in a Side-by-Side Comparison in the Same Patient (PLF)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, multi-center, observational, self-control study assessing screened and consented subjects undergoing instrumented posterolateral fusion for degenerative disc disease (DDD) at 1 to 2 contiguous levels between L1 and S1.
Patients diagnosed with DDD will be screened for enrollment based on inclusion and exclusion criteria outlined in this protocol. Subjects who are successfully screened and sign an informed consent will undergo PLF surgery utilizing PureGen, Alphagraft ProFuse Demineralized Bone Scaffold (DBS), and ZODIAC, Illico, or Xenon Fixation system (pedicle screw and rod fixation system)
Subjects will be followed at 6 weeks, 3, 6, 12 and 24 month post-operative visits. Standard radiographs will be taken at these visits to evaluate fusion rate and quality. Oswestry Disability Index (ODI) and Visual Analog Scale (VAS) self-assessment questionnaires and neurological exams will be administered to measure pain and function scores. A computerized tomography (CT) scan will be taken at the 6-month to further assess rate and quality of fusion. A conditional 12 and 24 month post operative CT may also be taken. Procedure related and PureGen related adverse events will be monitored throughout the study.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Beverly Hills, California, United States
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Symptomatic lumbar degenerative disc disease in up to two contiguous levels between L1 and S1
- Subjects with back and/or leg pain indicated for posterior stabilization with or without decompression at any level and posterolateral fusion (PLF)
- Unresponsive to conservative treatment for at least 6 months
- Radiographic evidence of primary diagnosis
Exclusion Criteria:
- More than 2 levels requiring posterolateral fusion
- Spondylolisthesis greater than Grade I
- Prior failed fusion surgery at any lumbar level(s)
- Systemic or local infection in the disc or cervical spine, past or present
- Active systemic disease
- Osteoporosis, osteomalacia, or other metabolic bone disease that would significantly inhibit bone healing
- Use of other bone graft, Bone Morphogenetic Protein (BMP) or bone graft substitutes in addition to or in place of those products specified
- BMI greater than 40
- Use of post operative Spinal Cord Stimulator (SCS)
- Known or suspected history of alcohol and/or drug abuse
- Involved in pending litigation or worker's compensation related to the spine
- Pregnant or planning to become pregnant during the course of the study
- Insulin-dependent diabetes mellitus
- Life expectancy less than duration of study
- Any significant psychological disturbance that could impair consent process or ability to complete self-assessment questionnaires
- Undergoing chemotherapy or radiation treatment, or chronic use of oral or injected steroids or prolonged use of non-steroidal anti-inflammatory drugs.
- Known history of hypersensitivity or anaphylactic reaction to dimethyl sulfoxide (DMSO)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Study Graft Composite
AlphaGraft ProFuse Demineralized Bone Scaffold are soaked in PureGen according to Preparation for Use and handling technique. The graft composite is placed on the randomized study side contralateral to the autograft bone graft per surgeon's standard technique for PLF. The wound is closed according to surgeon's standard technique. Post operative care will be according to the site specific standard of care. An avoidance of heavy physical activity and limitations on working, lifting, bending etc. are common precautions post procedure. The decision to use a post operative orthosis is left to the discretion of the Investigator. |
PureGen Osteoprogenitor Cell Allograft with posterior transpedicular fixation.
|
Active Comparator: Control Graft Composite
Contralateral to the study graft composite, placement of posterolateral fusion graft composite containing iliac crest bone (5 cc/level/side) and local autograft composite (equal volume split with study side). Supplemental posterior pedicle screw fixation utilizing Zodiac, Illico or Xenon Spinal Fixation system.
|
Iliac Crest and Local Autograft Bone
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients With Fusion
Time Frame: 6, 12 and 24 month
|
Number of patients with fusion at the 6- and conditional 12- and 24-month visit
|
6, 12 and 24 month
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRO-000061
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lumbar Degenerative Disc Disease
-
NuVasiveCompleted
-
NuVasiveCompleted
-
Spine BioPharma, IncMCRARecruitingLumbar Degenerative Disc DiseaseUnited States
-
Synthes USA HQ, Inc.CompletedLumbar Degenerative Disc Disease
-
Assistance Publique - Hôpitaux de ParisTerminatedCervical Degenerative Disc Disease | Kyphosis | Lumbar Degenerative Disc DiseaseFrance
-
Foundation for Orthopaedic Research and EducationCoreLink, LLCCompletedDegenerative Disc Disease Lumbar
-
Medtronic Spinal and BiologicsTerminatedLumbar Degenerative Disc DiseaseUnited States
-
NuVasiveCompletedDegenerative Disc Disease, LumbarUnited States
-
NYU Langone HealthActive, not recruitingLumbar Degenerative Disc DiseaseUnited States
Clinical Trials on PureGen Osteoprogenitor Cell Allograft
-
Alphatec Spine, Inc.Terminated
-
Alphatec Spine, Inc.TerminatedLumbar Degenerative Disc DiseaseUnited States
-
Baxter Healthcare CorporationApatech, Inc.TerminatedDegenerative Disc Disease | Spinal Stenosis | Herniated Disc | Cervical Myelopathy | Spinal Cord Neoplasms | Spinal Deformity | Failed Back Surgery Syndrome | SpondylolithesisUnited States, Hungary, Netherlands
-
Charite University, Berlin, GermanyActive, not recruitingKidney Transplant Rejection | Antibody-mediated Rejection | Kidney Transplant FailureGermany
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedMyeloproliferative Disorders | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous LeukemiaUnited States
-
Memorial Sloan Kettering Cancer CenterTerminatedHodgkin Lymphoma | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Acute Myeloid Leukemia (AML) | Chronic Myeloid Leukemia (CML) | Acute Lymphoid Leukemia (ALL)United States
-
Centre Henri BecquerelUnknownLymphoblastic LymphomaBelgium, France